Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol.

Auteurs : Hendlisz A, Deleporte A, Vandeputte C, Charette N, Paesmans M, Guiot T, Garcia C, Flamen P
Année : 2015
Journal : BMJ Open
Volume : 5(3)
Pages : e007189

Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Auteurs : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaeys G, Goldman S, Ghanem G, Flamen P
Année : 2015
Journal : Mol Imaging Biol
Volume : 17(5)
Pages : 697-703

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Auteurs : Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, van Dongen GA, Everaert H, Vaes M, Bron D
Année : 2015
Journal : Eur J Nucl Med Mol Imaging
Volume : 42(8)
Pages : 1304-14